Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02112916
Title Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lymphoblastic lymphoma

T-cell acute lymphoblastic leukemia

Therapies

Cyclophosphamide

Vincristine Sulfate

Ifosfamide

Pegaspargase

Methotrexate

Cytarabine

Mercaptopurine

Thioguanine

Leucovorin

Daunorubicin

Dexamethasone

Bortezomib

Etoposide

Doxorubicin

Age Groups: adult | child
Covered Countries USA | CAN


No variant requirements are available.